Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Cevoli

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
International Journal of Environmental Research and Public Health|September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different PredictorsRaffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Pain and Therapy|March 29, 2021
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter StudyRaffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Pain and Therapy|September 26, 2021
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 PatientsRaffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Frontiers in Neurology|January 3, 2022
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in MenRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
Journal of Neurology|May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
The Journal of Headache and Pain|October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Cephalalgia : an International Journal of Headache|April 25, 2025
Evidence-based guidelines for the pharmacological treatment of migraine, summary versionRaffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia : an International Journal of Headache|April 25, 2025
Evidence-based guidelines for the pharmacological treatment of migraineRaffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
International Journal of Environmental Research and Public Health|September 9, 2022
Excellent Response to OnabotulinumtoxinA: Different Definitions, Different PredictorsRaffaele Ornello, Carlo Baraldi, Fayyaz Ahmed, et al.
Pain and Therapy|March 29, 2021
Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter StudyRaffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Pain and Therapy|September 26, 2021
Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 PatientsRaffaele Ornello, Fayyaz Ahmed, Andrea Negro, et al.
Frontiers in Neurology|January 3, 2022
Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in MenRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
The Journal of Headache and Pain|March 20, 2022
Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen studyRaffaele Ornello, Carlo Baraldi, Simona Guerzoni, et al.
Journal of Neurology|May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
The Journal of Headache and Pain|October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Cephalalgia : an International Journal of Headache|April 25, 2025
Evidence-based guidelines for the pharmacological treatment of migraine, summary versionRaffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Cephalalgia : an International Journal of Headache|April 25, 2025
Evidence-based guidelines for the pharmacological treatment of migraineRaffaele Ornello, Valeria Caponnetto, Fayyaz Ahmed, et al.
Neurology|January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA CohortEdoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Pageof 15